Highlights

  • Paradigm Biopharmaceuticals (ASX:PAR) completed enrolment in its pivotal Phase 3 PARA_OA_012 osteoarthritis trial.
  • The study enrolled 538 participants across 65 clinical sites in four countries.
  • Interim analysis is expected in Q3'2026, with top-line Phase 3 results targeted for Q1'2027.
  • Zilosul is being evaluated as a potential treatment for pain associated with knee osteoarthritis.

Paradigm Biopharmaceuticals (ASX:PAR) has reached a major milestone in the development of Zilosul after completing enrolment in its pivotal Phase 3 knee osteoarthritis trial.

The completed recruitment moves the company closer to its most important clinical data points, with an interim analysis expected in 2026 and final trial results expected in 2027.

However, the outcome remains dependent on whether Zilosul demonstrates meaningful clinical benefit in a large-scale placebo-controlled study.

What Happened?

On 15 June 2026, Paradigm announced completion of enrolment in PARA_OA_012, its pivotal Phase 3 trial evaluating Zilosul.

The trial enrolled 538 participants, exceeding the original target of 466 patients.

Participants were recruited across 65 clinical sites in Australia, the United States, Hong Kong and Moldova.

Zilosul is Paradigm’s injectable formulation of pentosan polysulfate sodium (iPPS), administered at 2mg/kg twice weekly for six weeks.

The trial is evaluating whether Zilosul can reduce pain associated with knee osteoarthritis compared with placebo.

Why It Matters

Completing enrolment removes a key operational risk in clinical development, as recruitment delays can significantly affect timelines and costs.

The next important stage is the analysis of clinical data to determine whether Zilosul demonstrates a meaningful treatment effect.

Osteoarthritis is a widespread condition associated with chronic pain and reduced mobility, while current treatments are largely focused on symptom management.

A therapy capable of providing longer-lasting pain reduction could address an unmet medical need.

However, Paradigm remains heavily dependent on the outcome of this single Phase 3 program.

The Numbers

The PARA_OA_012 trial includes:

  • 538 enrolled participants versus the original target of 466.
  • 65 clinical sites across four countries.
  • Zilosul dosing of 2mg/kg administered subcutaneously twice weekly for six weeks.

The primary endpoint is the change from baseline in Weekly Average Daily Pain score at Day 112.

Secondary endpoints include physical function, patient global assessment, responder rates and imaging-based structural measures.

The interim-analysis population is expected to complete Day 112 assessments in Q3'2026.

Paradigm expects database lock and preparation activities during August 2026, followed by an independent Data Safety Monitoring Board review in September 2026.

Top-line Phase 3 results are expected in Q1'2027.

The company raised A$21.38 million through an institutional Placement and Share Purchase Plan and reported approximately A$15.37 million in cash at June 2026.

The Bigger Picture

Zilosul is based on repurposing pentosan polysulfate sodium, a compound with previous medical applications, for osteoarthritis treatment.

Paradigm has previously reported biomarker findings suggesting effects on cartilage degradation, inflammation and pain-related pathways.

The company has also reported that an early Data Safety Monitoring Board review found no material safety concerns and recommended continuation without trial changes.

The review supported trial continuation but did not provide confirmation of efficacy.

Beyond clinical development, Paradigm has pursued licensing discussions and research collaborations focused on understanding osteoarthritis-related disease mechanisms.

The Bull Case

The positive case for Paradigm Biopharmaceuticals (ASX:PAR) is based on the potential of Zilosul to address a large osteoarthritis treatment market.

The completed Phase 3 enrolment provides a clear pathway towards important clinical data milestones.

The company has already generated earlier-stage biomarker and clinical observations supporting further investigation of the treatment approach.

A successful Phase 3 outcome could support regulatory discussions, commercial partnerships and future development opportunities.

Risks Investors Should Understand

Paradigm Biopharmaceuticals (ASX:PAR)’s Business faces risks including clinical trial failure, regulatory uncertainty, funding requirements and dependence on a single lead program.

The interim analysis may not demonstrate sufficient efficacy, and safety findings alone do not predict success against the primary pain endpoint.

Even positive Phase 3 results would require regulatory review before commercial approval.

The company may require additional funding to continue development depending on timelines and outcomes.

Earlier biomarker and Phase 2 observations may not translate into successful Phase 3 results.

What Comes Next?

The next major milestone is the interim analysis expected around Q3'2026 following completion of Day 112 assessments.

Investors will monitor the September 2026 Data Safety Monitoring Board review, interim findings and preparation for top-line Phase 3 results expected in Q1'2027.

Further licensing discussions and regulatory strategy updates will also remain relevant.

Conclusion

Paradigm Biopharmaceuticals (ASX:PAR) has completed enrolment in its pivotal Phase 3 Zilosul trial, moving the company closer to the clinical data that will determine the future of the program.

The trial has exceeded its recruitment target and progressed through an early safety review without reported concerns.

However, the key question remains whether Zilosul can demonstrate meaningful pain reduction in patients with knee osteoarthritis. The upcoming interim analysis and final Phase 3 results will determine whether the treatment moves from clinical promise towards potential approval.